ImmuneXcite is a privately held biotech company based in Lexington, Mass., that is developing the next generation of immune-activating anti-tumor biotherapeutics against a wide range of cancers using a fundamentally novel immunotherapy platform. The company's mAbXcite platform develops novel therapies that recruit complement and neutrophils, the first responders of the immune system, to mount a natural and potent attack on cancer cells. ImmuneXcite has several lead drug candidates, based on its mAbXcite platform, for cancers with high unmet medical needs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/07/14 | $3,580,000 | Series B | ||
| 03/30/16 | $8,600,000 | Series A-1 |
Cormorant Asset Management Partners Innovation Fund Sanofi-Genzyme BioVentures | undisclosed |
